These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Differential sensitivity to NaCl for inhibitors and substrates that recognize mutually exclusive binding sites on the neuronal transporter of dopamine in rat striatal membranes. Tidjane Corera A, Do-Régo JC, Costentin J, Bonnet JJ. Neurosci Res; 2001 Mar; 39(3):319-25. PubMed ID: 11248372 [Abstract] [Full Text] [Related]
4. Binding of uptake blockers to the neuronal dopamine transporter: further investigation about cationic and anionic requirements. Corera AT, Costentin J, Bonnet JJ. Naunyn Schmiedebergs Arch Pharmacol; 2000 Sep; 362(3):213-21. PubMed ID: 10997723 [Abstract] [Full Text] [Related]
5. Halogenated mazindol analogs as potential inhibitors of the cocaine binding site at the dopamine transporter. Houlihan WJ, Boja JW, Parrino VA, Kopajtic TA, Kuhar MJ. J Med Chem; 1996 Dec 06; 39(25):4935-41. PubMed ID: 8960553 [Abstract] [Full Text] [Related]
9. Translocation of dopamine and binding of 2 beta-carbomethoxy-3 beta-(4-fluorophenyl) tropane (WIN 35,428) measured under identical conditions in rat striatal synaptosomal preparations. Inhibition by various blockers. Xu C, Coffey LL, Reith ME. Biochem Pharmacol; 1995 Jan 31; 49(3):339-50. PubMed ID: 7857321 [Abstract] [Full Text] [Related]
10. Isothiocyanate derivatives of cocaine: irreversible inhibition of ligand binding at the dopamine transporter. Boja JW, Rahman MA, Philip A, Lewin AH, Carroll FI, Kuhar MJ. Mol Pharmacol; 1991 Mar 31; 39(3):339-45. PubMed ID: 1826041 [Abstract] [Full Text] [Related]
12. Binding domains for blockers and substrates on the dopamine transporter in rat striatal membranes studied by protection against N-ethylmaleimide-induced reduction of [3H]WIN 35,428 binding. Xu C, Coffey LL, Reith ME. Naunyn Schmiedebergs Arch Pharmacol; 1997 Jan 31; 355(1):64-73. PubMed ID: 9007844 [Abstract] [Full Text] [Related]
13. Studies of the biogenic amine transporters. 1. Dopamine reuptake blockers inhibit [3H]mazindol binding to the dopamine transporter by a competitive mechanism: preliminary evidence for different binding domains. Dersch CM, Akunne HC, Partilla JS, Char GU, de Costa BR, Rice KC, Carroll FI, Rothman RB. Neurochem Res; 1994 Feb 31; 19(2):201-8. PubMed ID: 8183430 [Abstract] [Full Text] [Related]
14. Effect of CH3HgCl and several transition metals on the dopamine neuronal carrier; peculiar behaviour of Zn2+. Bonnet JJ, Benmansour S, Amejdki-Chab N, Costentin J. Eur J Pharmacol; 1994 Jan 01; 266(1):87-97. PubMed ID: 8137886 [Abstract] [Full Text] [Related]
16. Binding domains for blockers and substrates on the cloned human dopamine transporter studied by protection against N-ethylmaleimide-induced reduction of 2 beta-carbomethoxy-3 beta-(4-fluorophenyl)[3H]tropane ([3H]WIN 35,428) binding. Reith ME, Xu C, Coffey LL. Biochem Pharmacol; 1996 Nov 08; 52(9):1435-46. PubMed ID: 8937455 [Abstract] [Full Text] [Related]
19. [3H]WIN 35,428 ([3H]CFT) binds to multiple charge-states of the solubilized dopamine transporter in primate striatum. Gracz LM, Madras BK. J Pharmacol Exp Ther; 1995 Jun 08; 273(3):1224-34. PubMed ID: 7791095 [Abstract] [Full Text] [Related]